Optimal equation for estimation of glomerular filtration rate in autosomal dominant polycystic kidney disease: influence of tolvaptan
Background The reliability of various equations for estimating the GFR in ADPKD patients and the influence of tolvaptan on the resulting estimates have not been examined when GFR is calculated on the basis of inulin clearance. Methods We obtained baseline and on-tolvaptan measured GFRs (mGFRs), calc...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental nephrology 2018-10, Vol.22 (5), p.1213-1223 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1223 |
|---|---|
| container_issue | 5 |
| container_start_page | 1213 |
| container_title | Clinical and experimental nephrology |
| container_volume | 22 |
| creator | Yamaguchi, Tsuyoshi Higashihara, Eiji Okegawa, Takatsugu Miyazaki, Isao Nutahara, Kikuo |
| description | Background
The reliability of various equations for estimating the GFR in ADPKD patients and the influence of tolvaptan on the resulting estimates have not been examined when GFR is calculated on the basis of inulin clearance.
Methods
We obtained baseline and on-tolvaptan measured GFRs (mGFRs), calculated on the basis of inulin clearance, in 114 ADPKD, and these mGFRs were compared with eGFRs calculated according to four basic equations: the MDRD, CKD-EPI, and JSN-CKDI equations and the Cockcroft–Gault formula, as well as the influence of tolvaptan and of inclusion of cystatin C on accuracy of the results. Accuracy of each of the seven total equations was evaluated on the basis of the percentage of eGFR values within mGFR ± 30% (P
30
).
Results
mGFRs were distributed throughout CKD stages 1–5. Regardless of the CKD stage, P
30
s of the MDRD, CKD-EPI, and JSN-CKDI equations did not differ significantly between baseline values and on-tolvaptan values. In CKD 1–2 patients, P
30
of the CKD-EPI equation was 100.0%, whether or not the patient was on-tolvaptan. In CKD 3–5 patients, P
30
s of the MDRD, CKD-EPI, and JSN-CKDI equations were similar. For all four equations, regression coefficients and intercepts did not differ significantly between baseline and on-tolvaptan values, but accuracy of the Cockcroft–Gault formula was inferior to that of the other three equations. Incorporation of serum cystatin C reduced accuracy.
Conclusions
The CKD-EPI equation is most reliable, regardless of the severity of CKD. Tolvaptain intake has minimal influence and cystatin C incorporation does not improve accuracy. |
| doi_str_mv | 10.1007/s10157-018-1574-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2043169199</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2042475420</sourcerecordid><originalsourceid>FETCH-LOGICAL-c494t-5f14a62f413d5b2a9b933efb8047e0a901f36fcc7d8c1c877b67a39d4e0b60473</originalsourceid><addsrcrecordid>eNp1kc1OHyEUxUmjqdb2AboxJG7cjPI1w9CdMdo2MXFj14RhLmYsAyPMNPk_gO8t09E2MXF1gPu75wIHoa-UnFFC5HmmhNayIrStioqKfUCHVHBZSanUXllzwSoqa3qAPuX8QAhpVa0-ogOmZKtU2xyip9tpHkbjMTwuZh5iwC4mDHk9_LuNDt_7OEJavEnYDX5OW6EI4CFgs8wxx9Wij-MQTJjxFP3O7oqHxb-HPsAO90MGk-FbaXB-gWBhNZ6j_2Om2YTPaN8Zn-HLix6hX9dXd5c_qpvb7z8vL24qK5SYq9pRYRrmBOV93TGjOsU5uK4lQgIxilDHG2et7FtLbStl10jDVS-AdE1h-BE63XynFB-X8ko9DtmC9yZAXLJmRHDaKKpUQU_eoA9xSaHcbqWYkLVgpFB0o2yKOSdwekrl59JOU6LXjPSWkS4Z6TUjzUrP8Yvz0o3Q_-t4DaUAbANyKYV7SP9Hv-_6DGN3nxs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2042475420</pqid></control><display><type>article</type><title>Optimal equation for estimation of glomerular filtration rate in autosomal dominant polycystic kidney disease: influence of tolvaptan</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Yamaguchi, Tsuyoshi ; Higashihara, Eiji ; Okegawa, Takatsugu ; Miyazaki, Isao ; Nutahara, Kikuo</creator><creatorcontrib>Yamaguchi, Tsuyoshi ; Higashihara, Eiji ; Okegawa, Takatsugu ; Miyazaki, Isao ; Nutahara, Kikuo</creatorcontrib><description>Background
The reliability of various equations for estimating the GFR in ADPKD patients and the influence of tolvaptan on the resulting estimates have not been examined when GFR is calculated on the basis of inulin clearance.
Methods
We obtained baseline and on-tolvaptan measured GFRs (mGFRs), calculated on the basis of inulin clearance, in 114 ADPKD, and these mGFRs were compared with eGFRs calculated according to four basic equations: the MDRD, CKD-EPI, and JSN-CKDI equations and the Cockcroft–Gault formula, as well as the influence of tolvaptan and of inclusion of cystatin C on accuracy of the results. Accuracy of each of the seven total equations was evaluated on the basis of the percentage of eGFR values within mGFR ± 30% (P
30
).
Results
mGFRs were distributed throughout CKD stages 1–5. Regardless of the CKD stage, P
30
s of the MDRD, CKD-EPI, and JSN-CKDI equations did not differ significantly between baseline values and on-tolvaptan values. In CKD 1–2 patients, P
30
of the CKD-EPI equation was 100.0%, whether or not the patient was on-tolvaptan. In CKD 3–5 patients, P
30
s of the MDRD, CKD-EPI, and JSN-CKDI equations were similar. For all four equations, regression coefficients and intercepts did not differ significantly between baseline and on-tolvaptan values, but accuracy of the Cockcroft–Gault formula was inferior to that of the other three equations. Incorporation of serum cystatin C reduced accuracy.
Conclusions
The CKD-EPI equation is most reliable, regardless of the severity of CKD. Tolvaptain intake has minimal influence and cystatin C incorporation does not improve accuracy.</description><identifier>ISSN: 1342-1751</identifier><identifier>EISSN: 1437-7799</identifier><identifier>DOI: 10.1007/s10157-018-1574-2</identifier><identifier>PMID: 29789986</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Accuracy ; Aged ; Antidiuretic Hormone Receptor Antagonists - therapeutic use ; Creatinine ; Cystatin C ; Epidermal growth factor receptors ; Glomerular Filtration Rate ; Humans ; Inulin ; Kidney diseases ; Mathematical models ; Medicine ; Medicine & Public Health ; Middle Aged ; Nephrology ; Original Article ; Polycystic kidney ; Polycystic Kidney, Autosomal Dominant - drug therapy ; Polycystic Kidney, Autosomal Dominant - physiopathology ; Reproducibility of Results ; Retrospective Studies ; Tolvaptan - therapeutic use ; Urology</subject><ispartof>Clinical and experimental nephrology, 2018-10, Vol.22 (5), p.1213-1223</ispartof><rights>Japanese Society of Nephrology 2018</rights><rights>Clinical and Experimental Nephrology is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c494t-5f14a62f413d5b2a9b933efb8047e0a901f36fcc7d8c1c877b67a39d4e0b60473</citedby><cites>FETCH-LOGICAL-c494t-5f14a62f413d5b2a9b933efb8047e0a901f36fcc7d8c1c877b67a39d4e0b60473</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10157-018-1574-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10157-018-1574-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29789986$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamaguchi, Tsuyoshi</creatorcontrib><creatorcontrib>Higashihara, Eiji</creatorcontrib><creatorcontrib>Okegawa, Takatsugu</creatorcontrib><creatorcontrib>Miyazaki, Isao</creatorcontrib><creatorcontrib>Nutahara, Kikuo</creatorcontrib><title>Optimal equation for estimation of glomerular filtration rate in autosomal dominant polycystic kidney disease: influence of tolvaptan</title><title>Clinical and experimental nephrology</title><addtitle>Clin Exp Nephrol</addtitle><addtitle>Clin Exp Nephrol</addtitle><description>Background
The reliability of various equations for estimating the GFR in ADPKD patients and the influence of tolvaptan on the resulting estimates have not been examined when GFR is calculated on the basis of inulin clearance.
Methods
We obtained baseline and on-tolvaptan measured GFRs (mGFRs), calculated on the basis of inulin clearance, in 114 ADPKD, and these mGFRs were compared with eGFRs calculated according to four basic equations: the MDRD, CKD-EPI, and JSN-CKDI equations and the Cockcroft–Gault formula, as well as the influence of tolvaptan and of inclusion of cystatin C on accuracy of the results. Accuracy of each of the seven total equations was evaluated on the basis of the percentage of eGFR values within mGFR ± 30% (P
30
).
Results
mGFRs were distributed throughout CKD stages 1–5. Regardless of the CKD stage, P
30
s of the MDRD, CKD-EPI, and JSN-CKDI equations did not differ significantly between baseline values and on-tolvaptan values. In CKD 1–2 patients, P
30
of the CKD-EPI equation was 100.0%, whether or not the patient was on-tolvaptan. In CKD 3–5 patients, P
30
s of the MDRD, CKD-EPI, and JSN-CKDI equations were similar. For all four equations, regression coefficients and intercepts did not differ significantly between baseline and on-tolvaptan values, but accuracy of the Cockcroft–Gault formula was inferior to that of the other three equations. Incorporation of serum cystatin C reduced accuracy.
Conclusions
The CKD-EPI equation is most reliable, regardless of the severity of CKD. Tolvaptain intake has minimal influence and cystatin C incorporation does not improve accuracy.</description><subject>Accuracy</subject><subject>Aged</subject><subject>Antidiuretic Hormone Receptor Antagonists - therapeutic use</subject><subject>Creatinine</subject><subject>Cystatin C</subject><subject>Epidermal growth factor receptors</subject><subject>Glomerular Filtration Rate</subject><subject>Humans</subject><subject>Inulin</subject><subject>Kidney diseases</subject><subject>Mathematical models</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Nephrology</subject><subject>Original Article</subject><subject>Polycystic kidney</subject><subject>Polycystic Kidney, Autosomal Dominant - drug therapy</subject><subject>Polycystic Kidney, Autosomal Dominant - physiopathology</subject><subject>Reproducibility of Results</subject><subject>Retrospective Studies</subject><subject>Tolvaptan - therapeutic use</subject><subject>Urology</subject><issn>1342-1751</issn><issn>1437-7799</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kc1OHyEUxUmjqdb2AboxJG7cjPI1w9CdMdo2MXFj14RhLmYsAyPMNPk_gO8t09E2MXF1gPu75wIHoa-UnFFC5HmmhNayIrStioqKfUCHVHBZSanUXllzwSoqa3qAPuX8QAhpVa0-ogOmZKtU2xyip9tpHkbjMTwuZh5iwC4mDHk9_LuNDt_7OEJavEnYDX5OW6EI4CFgs8wxx9Wij-MQTJjxFP3O7oqHxb-HPsAO90MGk-FbaXB-gWBhNZ6j_2Om2YTPaN8Zn-HLix6hX9dXd5c_qpvb7z8vL24qK5SYq9pRYRrmBOV93TGjOsU5uK4lQgIxilDHG2et7FtLbStl10jDVS-AdE1h-BE63XynFB-X8ko9DtmC9yZAXLJmRHDaKKpUQU_eoA9xSaHcbqWYkLVgpFB0o2yKOSdwekrl59JOU6LXjPSWkS4Z6TUjzUrP8Yvz0o3Q_-t4DaUAbANyKYV7SP9Hv-_6DGN3nxs</recordid><startdate>20181001</startdate><enddate>20181001</enddate><creator>Yamaguchi, Tsuyoshi</creator><creator>Higashihara, Eiji</creator><creator>Okegawa, Takatsugu</creator><creator>Miyazaki, Isao</creator><creator>Nutahara, Kikuo</creator><general>Springer Singapore</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20181001</creationdate><title>Optimal equation for estimation of glomerular filtration rate in autosomal dominant polycystic kidney disease: influence of tolvaptan</title><author>Yamaguchi, Tsuyoshi ; Higashihara, Eiji ; Okegawa, Takatsugu ; Miyazaki, Isao ; Nutahara, Kikuo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c494t-5f14a62f413d5b2a9b933efb8047e0a901f36fcc7d8c1c877b67a39d4e0b60473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Accuracy</topic><topic>Aged</topic><topic>Antidiuretic Hormone Receptor Antagonists - therapeutic use</topic><topic>Creatinine</topic><topic>Cystatin C</topic><topic>Epidermal growth factor receptors</topic><topic>Glomerular Filtration Rate</topic><topic>Humans</topic><topic>Inulin</topic><topic>Kidney diseases</topic><topic>Mathematical models</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Nephrology</topic><topic>Original Article</topic><topic>Polycystic kidney</topic><topic>Polycystic Kidney, Autosomal Dominant - drug therapy</topic><topic>Polycystic Kidney, Autosomal Dominant - physiopathology</topic><topic>Reproducibility of Results</topic><topic>Retrospective Studies</topic><topic>Tolvaptan - therapeutic use</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamaguchi, Tsuyoshi</creatorcontrib><creatorcontrib>Higashihara, Eiji</creatorcontrib><creatorcontrib>Okegawa, Takatsugu</creatorcontrib><creatorcontrib>Miyazaki, Isao</creatorcontrib><creatorcontrib>Nutahara, Kikuo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamaguchi, Tsuyoshi</au><au>Higashihara, Eiji</au><au>Okegawa, Takatsugu</au><au>Miyazaki, Isao</au><au>Nutahara, Kikuo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Optimal equation for estimation of glomerular filtration rate in autosomal dominant polycystic kidney disease: influence of tolvaptan</atitle><jtitle>Clinical and experimental nephrology</jtitle><stitle>Clin Exp Nephrol</stitle><addtitle>Clin Exp Nephrol</addtitle><date>2018-10-01</date><risdate>2018</risdate><volume>22</volume><issue>5</issue><spage>1213</spage><epage>1223</epage><pages>1213-1223</pages><issn>1342-1751</issn><eissn>1437-7799</eissn><abstract>Background
The reliability of various equations for estimating the GFR in ADPKD patients and the influence of tolvaptan on the resulting estimates have not been examined when GFR is calculated on the basis of inulin clearance.
Methods
We obtained baseline and on-tolvaptan measured GFRs (mGFRs), calculated on the basis of inulin clearance, in 114 ADPKD, and these mGFRs were compared with eGFRs calculated according to four basic equations: the MDRD, CKD-EPI, and JSN-CKDI equations and the Cockcroft–Gault formula, as well as the influence of tolvaptan and of inclusion of cystatin C on accuracy of the results. Accuracy of each of the seven total equations was evaluated on the basis of the percentage of eGFR values within mGFR ± 30% (P
30
).
Results
mGFRs were distributed throughout CKD stages 1–5. Regardless of the CKD stage, P
30
s of the MDRD, CKD-EPI, and JSN-CKDI equations did not differ significantly between baseline values and on-tolvaptan values. In CKD 1–2 patients, P
30
of the CKD-EPI equation was 100.0%, whether or not the patient was on-tolvaptan. In CKD 3–5 patients, P
30
s of the MDRD, CKD-EPI, and JSN-CKDI equations were similar. For all four equations, regression coefficients and intercepts did not differ significantly between baseline and on-tolvaptan values, but accuracy of the Cockcroft–Gault formula was inferior to that of the other three equations. Incorporation of serum cystatin C reduced accuracy.
Conclusions
The CKD-EPI equation is most reliable, regardless of the severity of CKD. Tolvaptain intake has minimal influence and cystatin C incorporation does not improve accuracy.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>29789986</pmid><doi>10.1007/s10157-018-1574-2</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1342-1751 |
| ispartof | Clinical and experimental nephrology, 2018-10, Vol.22 (5), p.1213-1223 |
| issn | 1342-1751 1437-7799 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2043169199 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Accuracy Aged Antidiuretic Hormone Receptor Antagonists - therapeutic use Creatinine Cystatin C Epidermal growth factor receptors Glomerular Filtration Rate Humans Inulin Kidney diseases Mathematical models Medicine Medicine & Public Health Middle Aged Nephrology Original Article Polycystic kidney Polycystic Kidney, Autosomal Dominant - drug therapy Polycystic Kidney, Autosomal Dominant - physiopathology Reproducibility of Results Retrospective Studies Tolvaptan - therapeutic use Urology |
| title | Optimal equation for estimation of glomerular filtration rate in autosomal dominant polycystic kidney disease: influence of tolvaptan |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T19%3A32%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Optimal%20equation%20for%20estimation%20of%20glomerular%20filtration%20rate%20in%20autosomal%20dominant%20polycystic%20kidney%20disease:%20influence%20of%20tolvaptan&rft.jtitle=Clinical%20and%20experimental%20nephrology&rft.au=Yamaguchi,%20Tsuyoshi&rft.date=2018-10-01&rft.volume=22&rft.issue=5&rft.spage=1213&rft.epage=1223&rft.pages=1213-1223&rft.issn=1342-1751&rft.eissn=1437-7799&rft_id=info:doi/10.1007/s10157-018-1574-2&rft_dat=%3Cproquest_cross%3E2042475420%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2042475420&rft_id=info:pmid/29789986&rfr_iscdi=true |